Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 400 participants.

Also called NCT02596555

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (enrolled count) (from the registry)
Sponsor
Prof. Stavros Konstantinides, MD (from the registry)
Registry
  • NCT NCT02596555
Other papers using this trial's data
  • Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial The Lancet. Haematology, 2021-09 DOI, PubMed 34363769

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02596555. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01 (actual); primary completion 2020-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
Acronym
PEITHO-2
Intervention (Drug)
Dabigatran
Lead sponsor
Prof. Stavros Konstantinides, MD (class: other)
Collaborator
European Georges Pompidou Hospital (class: other)

Record details

Record id
cardio:ct-nct02596555
Content hash
a978b4476539b52d5e741071db43b0d938e3d537b7d25614681dcd37c51d5782